Table 1.
Characteristics of the study population.
| Control (n = 8 + 2)a | VU (n = 9 + 1)a | IR (n = 12 + 3)a | INR (n = 8 + 0) 2 | |
|---|---|---|---|---|
| Age (years, IQR)b | 31 (44.25–28.75) | 35 (39–33.25) | 44 (47.5–35) | 48 (51.25–41) |
| Male gender (No., %) | 8 (80%)a | 9 (90%)a | 12 (80%)a | 8 (100%)a |
| CD4 + T-cell count (cells/mm3, IQR) | 748 (813.5–647) | 577.5 (835–445) | 600 (830–522) | 291 (322.25–242.25) |
| CD4/CD8 ratio (IQR) | 1.22 (1.45–1.09) | 0.60 (0.93–0.46) | 1.00 (1.21–0.91) | 0.71 (0.89–0.36) |
| HIV RNA Level (copies/mL, IQR) | – | 22,198 (9955–40,621) | < 20 | < 20 |
| Nadir CD4 + T-cell count (cells/mm3, IQR) | – | 577.5 (835–445) | 225 (256.5–116.5) | 132.5 (184.5–103.5) |
| Time since HIV diagnosis (years, IQR) | – | 5.4 (2.9–9.9) | 8.0 (4.5–13.9) | 11.8 (5.6–20.8) |
| Duration of ART (years, IQR)c | – | – | 6.1 (4.3–11.7) | 8.9 (4.6–12.7) |
| Framingham Risk Score (%, IQR) | 3.63 (2.5–1) | 2.73 (2–1) | 5.23 (7–2) | 5.29 (6–4) |
| Body mass index (kg/m2) | 21.89 (23.53–20.43) | 22.98 (25.88–22.58) | 22.45 (24.53–23.37) | 25.56 (26.63–24.61) |
| Glucose (mg/dL) | 92 (95–88.25) | 86.5 (91–83.25) | 91 (96–82) | 92 (97.5–88.25) |
| Creatinine (mg/dL) | 0.99 (1.04–0.93) | 0.95 (1.02–0.93) | 0.98 (1.08–0.89) | 0.98 (1.05–0.95) |
| Total cholesterol (mg/dL) | 173 (213–149.5) | 155 (173.75–152) | 190 (211.5–165) | 151.5 (199.75–144.25) |
| HDL cholesterol (mg/dL) | 64 (75.75–51.25) | 47.5 (53–42.25) | 54 (61–48.5) | 50 (58.5–43.25) |
| LDL cholesterol (mg/dL) | 92.5 (118–78.75) | 90.5 (99.5–87.25) | 106 (131–94.5) | 86.5 (118.5–70) |
| Triglycerides (mg/dL) | 68 (83.75–59.5) | 107 (136.5–70.75) | 102 (140.5–80.5) | 122 (148–81.25) |
a
Data are included for all individuals, including those for the 6-weeks longitudinal samples (initial + longitudinal).
b
IQR, interquartile range.
c
The ART regime described in Table S2.